Poxel SA, a research integrated pharmaceutical company, engages in developing products for metabolic diseases with a focus on Type 2 diabetes. It offers Imeglimin, an orally active adjunct for diet and exercises to improve glycemic control in patients with type 2 diabetes; Glucagon-like peptide-1 receptor agonist, an incretin hormone displaying glucose-dependent stimulation of insulin secretion and restoring the normal profile of insulin release in response to glucose; and AMP-activated protein kinase activator, an enzyme that controls whole-body energy metabolism by regulating glucose and fatty acid homeostasis in various peripheral tissues, such as skeletal muscle and liver. The company also provides Farnesoid X receptor-agonists to induce a decrease in cholesterol synthesis and release by the liver; Glucokinase activators that act as glucose sensor by phosphorylating glucose in various key organs, such as liver, pancreas, intestine, and brain to control glucose induced insulin secretion in beta cells and glucose metabolism in the liver; and 11ß-Hydroxysteroid dehydrogenase type 1 inhibitors to regulate glucocorticoid levels in adipose tissue, skeletal muscles, and liver. Poxel was incorporated in 2009 and is based in Lyon, France.
Type
Public
HQ
Lyon, FR
Founded
2009
Size (employees)
19 (est)
Website
poxel.com
Poxel was founded in 2009 and is headquartered in Lyon, FR

Key People at Poxel

Thomas Kuhn

Thomas Kuhn

CEO, co-founder

Poxel Office Locations

Poxel has an office in Lyon
Lyon, FR (HQ)
200 Avenue Jean Jaures

Poxel Data and Metrics

Poxel Financial Metrics

EUR

Market capitalization (21-Sep-2017)

131.4 m

Closing share price (21-Sep-2017)

5.8
Poxel's current market capitalization is €131.4 m.
Show all financial metrics

Poxel Market Value History

Traffic Overview of Poxel

Poxel News and Updates

BRIEF-Poxel closes 26.5 million euro capital increase

* Announces the closing of a capital increase of 3,400,000 new ordinary shares without preferential subscription rights reserved for a category of investors for a total amount of 26.5 million ($29.36 million) Source text for Eikon: Further company coverage: ($1 = 0.9024 euros) (Gdynia Newsro…

BRIEF-Poxel cash and cash equivalents were 32.1 million euros as of June 30

* As of June 30, 2016, cash and cash equivalents were 32.1 million euros ($35.53 million) compared to 29.5 million euros on June 30, 2015 Source text for Eikon: See also: Further company coverage: ($1 = 0.9033 euros) (Gdynia Newsroom:)

BRIEF-Poxel announces positive results PXL770 trial

* Poxel announces positive results from the first stage of the ongoing PXL770 phase 1 trial

Poxel Company Life and Culture

You may also be interested in